Pulse Biosciences マネジメント
マネジメント 基準チェック /24
Pulse Biosciencesの CEO はPaul LaVioletteで、 Jan2025年に任命され、 の在任期間は 1.67年です。 の年間総報酬は$ 14.20Mで、 5%給与と95%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.022%を直接所有しており、その価値は$ 773.22K 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と8.8年です。
主要情報
Paul LaViolette
最高経営責任者
US$14.2m
報酬総額
| CEO給与比率 | 4.99% |
| CEO在任期間 | 1.7yrs |
| CEOの所有権 | 0.02% |
| 経営陣の平均在職期間 | 2.9yrs |
| 取締役会の平均在任期間 | 8.8yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Sep 09
PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook
Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
ナラティブ更新 • Aug 26
PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access
Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.ナラティブ更新 • Aug 12
PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market
The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.
新しいナラティブ • Aug 07
Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability
Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Jul 29
PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook
Analysts have lifted their price target on Pulse Biosciences to $35 from $30, citing preliminary support for the nsPFA platform's safety and efficacy profile in cardiac ablation and its potential to address a large electrophysiology market opportunity. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences points to growing confidence in the potential of its nanosecond pulsed field ablation, or nsPFA, platform in cardiac ablation.ナラティブ更新 • Jul 10
PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market
Analysts have lifted the fair value estimate for Pulse Biosciences from about $22 to roughly $30.67 per share, citing the company’s differentiated nanosecond pulsed field ablation platform and the roughly $3 billion electrophysiologists ablation market opportunity as key drivers behind a Street price target of $32. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform and how that might justify the latest fair value estimate and price targets around US$32 per share.ナラティブ更新 • Jun 26
PLSE: Nanosecond Cardiac Ablation Platform Will Pursue Expanding Electrophysiology Opportunity
Analysts raised their price target on Pulse Biosciences stock from $30 to $32, citing its differentiated nanosecond pulsed field cardiac ablation platform and the $3 billion electrophysiology ablation market, which they estimate is growing 10% to 15% annually, with potential for the company to capture a meaningful share. Analyst Commentary Bullish analysts covering Pulse Biosciences emphasize that the stock is now being valued around a clearly defined opportunity in cardiac ablation, supported by a specific US$32 price target.新しいナラティブ • Feb 09
Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?分析記事 • Dec 21
Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jun 12
Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Feb 07
We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Pulse...Seeking Alpha • May 16
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure. Read the full article on Seeking Alpha分析記事 • May 10
We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pulse Biosciences...分析記事 • Sep 04
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Mar 08
Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$80m |
| Mar 31 2026 | n/a | n/a | -US$75m |
| Dec 31 2025 | US$14m | US$709k | -US$73m |
| Sep 30 2025 | n/a | n/a | -US$75m |
| Jun 30 2025 | n/a | n/a | -US$68m |
| Mar 31 2025 | n/a | n/a | -US$60m |
| Dec 31 2024 | US$3m | n/a | -US$54m |
報酬と市場: Paulの 総報酬 ($USD 14.20M ) は、 US市場 ($USD 6.99M ) の同規模の企業の平均を上回っています。
報酬と収益: Paulの報酬は増加しましたが、会社は利益を上げていません。
CEO
Paul LaViolette (68 yo)
1.7yrs
在職期間
US$14,200,988
報酬
Mr. Paul Arthur LaViolette, M.B.A. is Member of Advisory Board of Carvolix SA from April 2026. He is Director of Vibrato Medical, Inc. Mr. LaViolette is President, Chief Executive Officer, at Pulse Bioscie...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 1.7yrs | US$14.20m | 0.022% $ 773.2k | |
| Chief Financial Officer | 1.6yrs | US$2.88m | 0.0022% $ 75.9k | |
| CTO & Director | 4yrs | US$869.89k | 0.40% $ 13.9m | |
| Chief Operating Officer | less than a year | データなし | 0.0057% $ 199.7k | |
| VP of Accounting | 1.2yrs | データなし | データなし | |
| General Counsel & Corporate Secretary | 5.3yrs | データなし | データなし | |
| Vice President of Human Resources | 6.5yrs | データなし | データなし | |
| Senior Vice President of Engineering | 5yrs | データなし | データなし | |
| Chief Medical Officer | 3.3yrs | データなし | データなし | |
| Chief Science Officer of Cardiac Surgery | 2.9yrs | データなし | データなし | |
| Chief Medical Officer | 1.9yrs | データなし | データなし |
2.9yrs
平均在職期間
53.5yo
平均年齢
経験豊富な経営陣: PLSEの経営陣は 経験豊富 であると考えられます ( 2.9年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 2.1yrs | US$14.20m | 0.022% $ 773.2k | |
| CTO & Director | 11yrs | US$869.89k | 0.40% $ 13.9m | |
| Independent Director | 6.1yrs | US$412.74k | 0% $ 0 | |
| Independent Co-Chairman | 8.8yrs | US$633.14k | 68.45% $ 2.4b | |
| Independent Director | less than a year | データなし | データなし | |
| Independent Director | 9.6yrs | US$704.61k | 1.22% $ 42.6m | |
| Lead Independent Director | 8.8yrs | US$631.80k | 0% $ 0 |
8.8yrs
平均在職期間
60yo
平均年齢
経験豊富なボード: PLSEの 取締役会 は 経験豊富 であると考えられます ( 8.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/09 12:37 |
| 終値 | 2026/09/09 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Pulse Biosciences, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| William Plovanic | Canaccord Genuity |
| Keith Hinton | Freedom Capital Markets |
| Anthony Petrone | Mizuho Securities USA LLC |